Twinbeech Capital LP Sells 105,944 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Twinbeech Capital LP lowered its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 75.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 34,558 shares of the biopharmaceutical company's stock after selling 105,944 shares during the quarter. Twinbeech Capital LP owned about 0.05% of Celldex Therapeutics worth $873,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in Celldex Therapeutics by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 3,881,995 shares of the biopharmaceutical company's stock valued at $98,098,000 after buying an additional 12,213 shares during the period. Price T Rowe Associates Inc. MD lifted its position in Celldex Therapeutics by 23.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,557,136 shares of the biopharmaceutical company's stock valued at $89,890,000 after buying an additional 676,771 shares during the period. Point72 Asset Management L.P. lifted its position in Celldex Therapeutics by 50.8% during the fourth quarter. Point72 Asset Management L.P. now owns 2,515,972 shares of the biopharmaceutical company's stock valued at $63,579,000 after buying an additional 847,264 shares during the period. Deep Track Capital LP purchased a new position in Celldex Therapeutics during the fourth quarter valued at $38,919,000. Finally, Rock Springs Capital Management LP lifted its position in Celldex Therapeutics by 10.7% during the fourth quarter. Rock Springs Capital Management LP now owns 1,222,182 shares of the biopharmaceutical company's stock valued at $30,885,000 after buying an additional 118,404 shares during the period.

Analyst Upgrades and Downgrades

CLDX has been the subject of several recent research reports. UBS Group lowered their price objective on Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. Morgan Stanley lowered their price target on Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating for the company in a research report on Friday, May 9th. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 price target on shares of Celldex Therapeutics in a research report on Tuesday, May 6th. Finally, The Goldman Sachs Group lowered their price target on Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating for the company in a research report on Friday, May 9th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $53.90.

Celldex Therapeutics Price Performance

NASDAQ CLDX traded down $0.02 during trading hours on Friday, hitting $20.35. The company's stock had a trading volume of 477,438 shares, compared to its average volume of 897,536. Celldex Therapeutics, Inc. has a 12 month low of $14.40 and a 12 month high of $47.00. The company's 50 day simple moving average is $18.91 and its two-hundred day simple moving average is $22.42. The company has a market cap of $1.35 billion, a P/E ratio of -7.92 and a beta of 1.39.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. The business had revenue of $0.70 million during the quarter, compared to the consensus estimate of $1.08 million. As a group, research analysts predict that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.